Matinas BioPharma Announces 1-for-15 Reverse Stock Split

What Happened

• Matinas BioPharma Holdings, Inc. announced that its Board approved a 1-for-15 reverse stock split of the company’s common stock. The Company had previously received stockholder approval on June 23, 2025 to permit up to two reverse splits with an aggregate ratio between 1:2 and 1:199. The 1-for-15 reverse split will become effective at 12:01 a.m. Eastern Time on September 28, 2026, and shares are expected to trade on a split-adjusted basis under the existing symbol “MTNB” when the market opens that day. The new CUSIP after the split will be 576810 402.

Key Details

• Effective date/time: 12:01 a.m. ET on September 28, 2026; trading on split-adjusted basis expected when market opens Sept. 28, 2026.
• Ratio: one-for-fifteen (1:15).
• Fractional shares: no fractional shares will be issued; holders entitled to fractional shares will receive a proportional cash payment.
• Ownership/structure: each holder’s total shares will be divided by 15; percentage ownership and voting power remain essentially unchanged (except for minor adjustments from fractional-share cash-outs). Par value and number of authorized shares of common and preferred stock are unchanged.
• Transfer agent: holders in brokerage accounts do not need to act; holders with paper certificates may (but need not) send certificates to transfer agent VStock Transfer, LLC for reissuance.

Why It Matters

• For investors, a reverse stock split consolidates outstanding shares (reduces share count and increases the per-share price) but does not change a holder’s proportional ownership or the company’s underlying equity value, aside from minor rounding/cash-outs for fractional shares.
• The Company cautioned the reverse split does not guarantee continued listing on the NYSE American. Investors should note the new CUSIP and the effective/trading dates to confirm share counts and pricing in brokerage accounts.